Development of lung and muscle protein factories to deliver therapeutic monoclonal antibodies

Development of lung and muscle protein factories to deliver therapeutic monoclonal antibodies

Recombinant therapeutic proteins, of which monoclonal antibodies (mAbs) represent the largest market, are used to treat diseases including cancer, blood and immune disorders. The cost and complexity of large-scale production and purification of mAbs translates to high cost of therapy. We hypothesise...

Descripció completa

Dades bibliogràfiques
Autors principals:	Antepowicz, A, Tan, A, Pringle, A, Hyde, S, Gill, D
Format:	Conference item
Publicat:	Mary Ann Liebert Inc 2016

Ítems similars

Development of lung and muscle factories to deliver therapeutic monoclonal antibodies
per: Antepowicz, A
Publicat: (2018)

431. Lung antibody factory for passive immunisation against influenza
per: Tan, T, et al.
Publicat: (2016)

Lentiviral-mediated expression of monoclonal antibodies in the lung to protect against influenza
per: Du, Y, et al.
Publicat: (2020)

Antibody gene transfer for prophylaxis of respiratory syncytial virus (RSV) infection
per: Antepowicz, A, et al.
Publicat: (2018)

The lung as a factory to produce secreted intrapulmonary and circulatory proteins
per: Paul-Smith, M, et al.
Publicat: (2017)

Development of monoclonal antibody therapeutics for alzheimer's disease
per: Masatoshi Takeda
Publicat: (2022-01-01)

The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins
per: Paul-Smith, M, et al.
Publicat: (2018)

Monoclonal Antibodies as Neurological Therapeutics
per: Panagiotis Gklinos, et al.
Publicat: (2021-01-01)

Therapeutic monoclonal antibody for Sporotrichosis
per: Sandro eAlmeida
Publicat: (2012-11-01)

The development of gene therapy for diseases of the lung.
per: Gill, DR, et al.
Publicat: (2004)

Development of Therapeutic Monoclonal Antibodies for Emerging Arbovirus Infections
per: Leonardo F. Ormundo, et al.
Publicat: (2023-10-01)

Advances and challenges in therapeutic monoclonal antibodies drug development
per: Mariana Lopes dos Santos, et al.
Publicat: (2018-11-01)

Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development
per: Rosalynn Molden, et al.
Publicat: (2021-01-01)

Monoclonal antibodies for the therapeutic induction of tolerance.
per: Waldmann, H, et al.
Publicat: (1993)

Therapeutic potential of monovalent monoclonal antibodies.
per: Cobbold, S, et al.
Publicat: (1984)

The pharmacology and therapeutic applications of monoclonal antibodies
per: María Sofía Castelli, et al.
Publicat: (2019-12-01)

Development and validation of an analytical procedure for the determination of residual protein A in active substances of therapeutic monoclonal antibodies
per: E. V. Nozdrina, et al.
Publicat: (2024-03-01)

Therapeutic Monoclonal Antibodies against Cancer: Present and Future
per: Marisa Delgado, et al.
Publicat: (2023-12-01)

Development of an anti-Pseudomonas aeruginosa therapeutic monoclonal antibody WVDC-5244
per: Alexander M. Horspool, et al.
Publicat: (2023-04-01)

Development and Characterization of Monoclonal Antibodies for the Detection of Fish Protein
per: Yi-Tien Chen, et al.
Publicat: (2021-10-01)

Corrigendum: Therapeutic potential of monovalent monoclonal antibodies
per: Cobbold, S, et al.
Publicat: (1984)

Therapeutic Uses of Monoclonal Antibodies for COVID-19
per: Tarun Kumar Suvvari
Publicat: (2020-01-01)

Intramuscular rAAV2/8 mediated expression of etanercept in mice with collagen-induced arthritis
per: Habib, O, et al.
Publicat: (2019)

Expression profile of optimised SIV vector in the mouse lung at early timepoints post-delivery
per: Pringle, I, et al.
Publicat: (2018)

DEVELOPMENT AND PROPERTIES OF NEUTRALIZING MONOCLONAL ANTIBODIES FOR FUSION PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS
per: A. A. Kushch, et al.
Publicat: (2019-04-01)

Therapeutic potential of monoclonal antibodies to the leucocyte common antigen.
per: Bindon, C, et al.
Publicat: (1985)

Identification and characterisation of candidate monoclonal antibody Ebolavirus therapeutics
per: Donnellan, FR
Publicat: (2021)

Monoclonal antibodies and aptamers: The future therapeutics for Alzheimer's disease
per: Alvaro Barrera-Ocampo
Publicat: (2024-07-01)

Therapeutic monoclonal antibodies with a focus on hereditary angioedema
per: Bruce L. Zuraw, et al.
Publicat: (2023-01-01)

Monoclonal Antibodies Targeting Ion Channels and Their Therapeutic Potential
per: Aurélien Haustrate, et al.
Publicat: (2019-06-01)

The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras
per: Brian Kelley
Publicat: (2024-12-01)

Binding of omeprazole to protein targets identified by monoclonal antibodies
per: Naw May Pearl Cartee, et al.
Publicat: (2020-01-01)

Developing Monoclonal Antibodies for Immunohistochemistry
per: Jacqueline Cordell
Publicat: (2022-01-01)

Impact of Urea on Monoclonal Antibodies: Multiple Destabilization and Aggregation Effects for Therapeutic Immunoglobulin G Proteins
per: Ji Young Yang, et al.
Publicat: (2024-01-01)

Monoclonal antibody techniques. 50 years of development
per: Yulia S. Massino, et al.
Publicat: (2024-07-01)

Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
per: Liming Liu
Publicat: (2017-04-01)

Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
per: Antepowicz, A, et al.
Publicat: (2021)

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments
per: C Ian Mockridge, et al.
Publicat: (2022-01-01)

Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential.
per: Isaacs, J, et al.
Publicat: (1992)

Monoclonal antibodies: a review of therapeutic applications and future prospects
per: Mahmuda, Aliyu, et al.
Publicat: (2017)